Roche Holding stock: RBC keeps CHF 400.00 target for Roche Holding stock

Published on 10/19/2026 at 17:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche will publish third-quarter sales on October 22, 2026. Roche Holding stock costs EUR 408.95 on October 19, 2026 at 5:08 p.m. CEST in regular trading.

Analyst and reporting dates

RBC Capital maintained a CHF 400.00 target for Roche Holding on October 19, 2026.
Roche will publish third-quarter sales on October 22, 2026.
Roche Holding stock traded at EUR 408.95 at 5:08 p.m. CEST on October 19, 2026.
Roche Holding had a market capitalization of CHF 261.5 billion on October 19, 2026.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

RBC Capital maintained a CHF 400.00 target for Roche Holding on October 19, 2026, according to MarketScreener. The target is 4.06 percent above Roche's SIX price of CHF 384.40 at 5:01 p.m. CEST on October 19, 2026. At Lang & Schwarz, Roche Holding stock was trading at EUR 408.95 on October 19, 2026 at 5:08 p.m. CEST.

RBC target and SIX valuation

The RBC target gives investors a clear benchmark ahead of Roche's next company update. The CHF 400.00 target stands above the latest SIX quote of CHF 384.40, while RBC kept its Outperform view in the October 19, 2026 report.

Roche's share price on SIX remained within its 52-week range of CHF 270.80 to CHF 387.00 on October 19, 2026. The CHF 384.40 quote was 0.67 percent below the 52-week high, leaving the stock near the upper end of its annual range.

Sales date arrives October 22

Roche will publish third-quarter sales before the Swiss exchange opens on October 22, 2026, followed by a webcast from 2:00 p.m. to 3:30 p.m. CEST, according to Roche. The date is the next scheduled company event in the investor calendar.

Valuation remains measurable

Roche had a market capitalization of CHF 261.5 billion, a trailing price-to-earnings ratio of 24.75 and a dividend yield of 3.00 percent on October 19, 2026. These figures give the analyst target a valuation frame without turning it into an investment recommendation.

Comparison with peers

Roche Holding (SIX, CHF): P/E 24.75, market capitalization CHF 261.5 billion.

Novartis (NYSE, USD): P/E 22.92, market capitalization USD 285.3 billion.

AstraZeneca (Nasdaq, USD): P/E 24.69, market capitalization USD 255.7 billion.

Euro quote and Swiss valuation

The Lang & Schwarz quote of EUR 408.95 places the German-market indication above Roche's Swiss listing in nominal terms, but the two prices use different currencies and are not combined into one performance measure. Roche's position near its 52-week high and the CHF 400.00 analyst target provide the main reference points before the October 22 sales release. The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.